<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391142</url>
  </required_header>
  <id_info>
    <org_study_id>CSB-CHF</org_study_id>
    <nct_id>NCT02391142</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure</brief_title>
  <acronym>CSB-CHF</acronym>
  <official_title>Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of Cardiac Sympathetic Blockade on
      Mortality, re-hospitalization rate, symptoms, quality of life, exercise tolerance, cardiac
      structure, systolic function, electrical activities and concentration of B - type natriuretic
      peptide precursor in patients with Chronic Heart Failure.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization rate</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>cardiac sympathetic nerve block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lidocaine or ropivacaine epidural injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-cardiac sympathetic nerve block</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks</description>
    <arm_group_label>cardiac sympathetic nerve block</arm_group_label>
    <other_name>ropivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-70 years old

          -  more than 3 months of chronic heart failure history or clinical symptoms of heart
             failure last for more than 3 months (including acute episode of chronic heart
             failure), chronic heart failure diagnostic criteria refer to 2012ESC Guidelines for
             the diagnosis and treatment of acute and chronic heart failure

          -  NYHA functional class III-IV, ejection fraction ≤45%

          -  NT-proBNP&gt;400ng/L

        Exclusion Criteria:

          -  first episode of acute heart failure

          -  unrepaired valvular heart disease accompanied with Hemodynamic changes

          -  hypertrophic cardiomyopathy, pericardial disease, congenital heart disease, severe
             pulmonary hypertension

          -  Second-degree type 2 or worse sinoatrial or atrioventricular block without pacemaker
             therapy

          -  right heart failure caused by various diseases, respiratory failure or right heart
             failure induced by chronic obstructive pulmonary disease

          -  overt renal decompensation: serum creatinine＞2.1mg/dl(186umol/L)

          -  severe hepatic dysfunction, transaminase or alkaline phosphatase &gt; 3 times the upper
             limit of normal

          -  Cerebral vascular accident in three months( cerebral infarction, cerebral embolism,
             cerebral hemorrhage,etc)

          -  life expectancy shorter than 6 months

          -  patients with a previous or present history of tumour or precancerous lesions
             confirmed by pathological examination

          -  Spine Deformity or skin infection at puncture site

          -  participate in any clinical drug trials in the three months

          -  the patients who do not sign the informed consent, unable or unwilling to comply with
             the requirements of the protocol or unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fengqi Liu, PhD</last_name>
    <phone>86-451-85555241</phone>
    <email>fengqiliu1964@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengqi Liu</last_name>
      <phone>86-0451-85555241</phone>
      <email>fengqiliu1964@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Dan Ma</last_name>
      <phone>86-0451-85555240</phone>
      <email>madandoc@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>cardiac sympathetic nerve block</keyword>
  <keyword>sympathetic nervous system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

